Maintaining the voice of rare diseases in a new, virtual world: Insights from the European Conference on Rare Diseases (ECRD) 2020
Embracing European Reference Networks (ERNs) for patient engagement
Awareness of ERNs and education around their potential involvement needs to be a core focus to ensure that patients are at the centre of drug and trial development. Alpharmaxim have a deep understanding of the field of rare diseases and the challenges faced by patients in this unique area.
- Patients are at the heart of the focus of ERNs
- It can be challenging for patient groups and organisations to access ERNs
- Involving ERNs and patients at the earliest stage in the drug development process will help to ensure that patient-reported outcomes are realistic and achievable, ensuring that patient outcomes are improved
Be prepared to truly demonstrate your commitment to the rare disease field, particularly in these uncertain times.
“This is a good time for us to try and ride the wave of greater solidarity and think about our fellow people and trying to support everybody, even if they have no condition.”
Victoria Hedley, Rare Disease Policy Manager, Newcastle University
At Alpharmaxim, we have extensive experience in helping speciality healthcare companies across the world communicate with HCPs and patients, particularly in rare diseases. We are passionate about helping our clients tell their stories and fulfil their promises, and we aim to make a real difference to patients, families and healthcare professionals.
If you would like to know more, please visit our website www.alpharmaxim.com, or contact Sophie Jones on +44 (0)161 929 0400.